Quantinno Capital Management LP Acquires 39,222 Shares of Bioventus Inc. $BVS

Quantinno Capital Management LP boosted its holdings in shares of Bioventus Inc. (NASDAQ:BVS) by 119.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 72,023 shares of the company’s stock after buying an additional 39,222 shares during the period. Quantinno Capital Management LP’s holdings in Bioventus were worth $658,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd increased its position in shares of Bioventus by 17,156.2% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock worth $41,000 after acquiring an additional 5,490 shares in the last quarter. Diversified Trust Co bought a new position in Bioventus in the 1st quarter valued at about $100,000. Prelude Capital Management LLC bought a new position in Bioventus in the 3rd quarter valued at about $74,000. Mercer Global Advisors Inc. ADV acquired a new position in Bioventus during the 3rd quarter valued at about $78,000. Finally, Brooklyn Investment Group bought a new stake in Bioventus during the 4th quarter worth approximately $91,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently commented on BVS shares. Craig Hallum reissued a “buy” rating and issued a $18.00 price objective on shares of Bioventus in a research note on Thursday, August 6th. Canaccord Genuity Group upped their price target on Bioventus from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Monday. Weiss Ratings raised Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, August 6th. Cantor Fitzgerald restated an “overweight” rating and set a $15.00 price objective on shares of Bioventus in a research note on Monday. Finally, Barrington Research set a $18.00 target price on shares of Bioventus in a research note on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $16.80.

Bioventus Price Performance

Bioventus stock opened at $14.68 on Thursday. Bioventus Inc. has a 52 week low of $6.26 and a 52 week high of $15.89. The company’s 50 day moving average price is $11.67 and its two-hundred day moving average price is $10.05. The company has a quick ratio of 1.17, a current ratio of 1.69 and a debt-to-equity ratio of 0.83. The stock has a market cap of $1.23 billion, a P/E ratio of 19.07, a P/E/G ratio of 1.82 and a beta of 0.63.

Bioventus (NASDAQ:BVS) last released its earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.22. The company had revenue of $153.21 million during the quarter. Bioventus had a return on equity of 28.08% and a net margin of 9.36%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities analysts predict that Bioventus Inc. will post 0.79 earnings per share for the current year.

Bioventus Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.